Rainer Fietkau, MD, on Pancreatic Cancer: Initial Trial Results on Sequential Chemotherapy and Chemoradiotherapy
2022 ASCO Annual Meeting
Rainer Fietkau, MD, of Germany’s University Hospital Erlangen, discusses phase III findings of the CONKO-007 trial, which examined the role of sequential chemotherapy and chemoradiotherapy administered to patients with nonresectable locally advanced pancreatic cancer following standard-of-care chemotherapy (Abstract 4008).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So CONKO-007 study compared in a randomized Phase III trial the effect of chemoradiotherapy or chemotherapy following induction chemotherapy. We included the patients with nonresectable locally advanced pancreatic cancer. Following three months of induction therapy, restaging was performed and patients with new detected metastasis or insufficient dosage of chemotherapy were included. 525 patients were included. 366 patients were randomized.
Important, we had the following feature of the study. Nonresectability was confirmed a panel of five experienced surgeons. This was checked again following the whole therapy and surgery was recommended if an R0 resection seems to be possible. And, we succeeded, that in both arms about 36% of the patients were then treated with surgery. We think that this high number was due to the fact that surgery was often recommended in the second surgical evaluation.
The primary end point, the R0 resection, was evaluated in the 122 patients with resection. Following chemoradiotherapy, more R0 resections were possible. The rate of R1 resections was significantly lower. The OS rate of CRM negative tumor was significantly higher. Furthermore, we found significantly more complete remissions following chemoradiotherapy.
In a second analysis, for all randomized patients nearly all statistically different parameters remained significant. Complete remission rate, R1 resection rate, CRM positive or negative status, all in favor of chemoradiotherapy. Only the R0 resection rate was no more statistically different, but this did not translate into a better overall progression free survival or overall survival. But what is very important, is the effect of additional surgery. None of the patients without surgery survived five years, but 17.5% with additional surgery. Of course, these are no randomized data and are biased by patient selection, but it may show the important role of surgery of these patients.
Moreover, the best survival data we achieved for CRM or R0 resected patients was a five year survival rate of 35 to 27%. We found some hints that chemoradiotherapy improves this long term survival of surgically treated patients. Five year survival following chemoradiotherapy is 24% compared to 20% following chemotherapy alone. Of course, these results are not statistically different but may be a hint how the better R0 resection rate may potentially translate into a better survival.
In conclusion, we found that additional chemoradiotherapy to chemotherapy improves significantly the R0 resected rate, in surgically treated group but not in all randomized patients. Additional chemoradiotherapy improves the rate of R0 CRM negative resected significantly and very importantly, 36% of all randomized patients can be treated additionally with surgery, the five year survival of 17.5% compared to 0% without surgery. Overall this concept of induction chemotherapy, additional chemoradiotherapy and surgery, is visible, with a five year survival rate of 9.6% and selects a favorable subgroup of patients that has an impressive long term survival rate of up to 26%.
And the next steps in our analysis will be a further evaluation of prognostic parameters to select better patients who will benefit most from surgery and chemoradiotherapy.
The ASCO Post Staff
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Kevin Kalinsky, MD, of Winship Cancer Institute at Emory University, discuss phase II findings from the MAINTAIN trial, which showed a benefit in progression-free survival for patients with hormone receptor–positive/HER2-negative metastatic breast cancer when they switched to endocrine therapy and received ribociclib after disease progression on another CDK4/6 inhibitor (Abstract LBA1004).
The ASCO Post Staff
Courtney D. DiNardo, MD, MSCE, of The University of Texas MD Anderson Cancer Center, and Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University, discuss phase III results from the ASCEMBL trial, which showed that after more than 2 years of follow-up, asciminib continued to yield superior efficacy and better safety and tolerability vs bosutinib in patients with chronic myeloid leukemia (CML) in chronic phase. These results continue to support the use of this kinase inhibitor as a new CML therapy, says Dr. Cortes, with the potential to transform the standard of care (Abstract 7004).
The ASCO Post Staff
Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses findings from the COSMIC-021 study, which showed that cabozantinib plus atezolizumab demonstrated encouraging clinical activity with manageable toxicity in patients with inoperable locally advanced or metastatic urothelial carcinoma. The combination was administered as first-line therapy in cisplatin-based chemotherapy–eligible and –ineligible patients and as second- or later-line treatment in those who received prior immune checkpoint inhibitors (Abstract 4504).
The ASCO Post Staff
Martin McCabe, PhD, of the University of Manchester, discusses a phase III assessment of chemotherapy for patients with recurrent and primary refractory Ewing sarcoma. The trial, called rEECur, is the first study to provide comparative toxicity and survival data for the four most commonly used chemotherapy regimens in this disease. The analysis showed that high-dose ifosfamide is more effective in prolonging survival than topotecan plus cyclophosphamide (Abstract LBA2).
The ASCO Post Staff
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Domenica Lorusso, MD, PhD, of Italy’s Gemelli University Hospital, discuss phase III data from the MITO23 trial on single-agent trabectedin vs clinician’s choice of chemotherapy in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype. Although trabectedin has demonstrated antitumor activity in relapsed platinum-sensitive disease, it does not appear to improve survival outcomes when compared with standard chemotherapy in the BRCA-mutated population (Abstract LBA5504).